You are here
- Home
- Therapy Areas
- Cardiovascular
A 26-week, double blind, randomised, mulit-centre, phase IIIb, parallel group study to compare the efficacy and safety of rosuvastatin (40 mg) with atorvastatin (80 mg) in subjects with hypercholesterolaemia and coronary heart disease or CHD risk equivalents.
- Disease
- hypercholesterolaemia, diabetes type 2, dyslipidaemia
- Drug Name
- Crestor
- Generic Name
- rosuvastatin
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- IIIb
- Start Date
- Jan 18, 1971
- Study Name
- 4522IL/0103
- Study Id
- 4522IL/0103
- ClinicalTrials.gov ID
- Not Applicable
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
